X

Trial Profile

Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

16 May 2024 Planned End Date changed from 1 Oct 2025 to 1 Jun 2027.
05 Mar 2024 Planned End Date changed from 1 May 2024 to 1 Oct 2025.
05 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com